The Latest Cardiac and Vascular News
Veteran cardiovascular medical device executive to lead Company’s next phase of growth as CIRCA builds a differentiated cardiovascular access portfolio; Lee Geist transitions to Chief Operating Officer ENGLEWOOD, Colo., July 24, 2026 /PRNewswire/ — CIRCA Scientific, Inc., a…
MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the s
Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio’s oversubscribed pre-Series A round in the final close, supporting the next phase of clinical validation and commercialisation WELLINGTON, New Zealand, July 24, 2026 – Wellumio, a New Zealand medical technology company developing Axana®, a portable brain imaging […]
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu
Appointments to scale adoption of Caristo’s AI-powered cardiovascular technologies globally OXFORD, England and STAMFORD, Conn., July 23, 2026 /PRNewswire/ — Caristo Diagnostics, a global leader in AI-powered technologies for cardiovascular disease, today announced two additions to its…
Drive-side force sensing and a 1:1 motion-mimicking interface make every procedure a training-grade record of expert clinical skill KAUNAS, Lithuania, July 23, 2026 /PRNewswire/ — Sentante, the medical robotics company building a haptic, device-agnostic platform for remote vascular…
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…
Collaboration combines Evogene’s AI-driven computational chemistry platform with ELEO’s proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July…
WALTHAM, Mass.–(BUSINESS WIRE)–Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy (DCM). A potential best-in-class investigational genetic m
